Pyelonephritis

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, June 5, 2022
Titan, New Drug Application, Facebook, THE, Food, LinkedIn, Court, Class, Workforce, Pyelonephritis, FDA, GLOBE, WHY, Urinary tract infection, Spero, Food and Drug Administration, NASDAQ, Advertising, Twitter, Tebipenem, Lists of schools in England, NDA, I-Space (Chinese company), TO, Tobacco, Insurance

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Twitter, LMP, and Spero and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
New Drug Application, Mission statement, Company, HBR, Ownership, Infection, Food, Annual report, Income, Complicated, News, Treatment, Lists of schools in England, Workforce, FDA, GLOBE, Patient, Defendant, TWTR, Review, Musk, Spero, NYSE, Urinary tract infection, Tebipenem, NASDAQ, SEC, Population, LMP, NDA, Degenerative disease, U.S. Securities and Exchange Commission, Disclosure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Documentation, Relevant, Complaint, Cryptocurrency, Audit, Medical device, Renewable energy, Pharmaceutical industry, Forbes, Twitter, Pyelonephritis, P.C

By failing to timely disclose his ownership stake, Musk was able to acquire shares of Twitter less expensively during the Class Period.

Key Points: 
  • By failing to timely disclose his ownership stake, Musk was able to acquire shares of Twitter less expensively during the Class Period.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • For more information on the Spero class action go to: https://bespc.com/cases/SPRO
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SPERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 2, 2022
Legal, Professional Services, New Drug Application, District court, Company, HBR, Infection, Food, Court, Jeanne Eagels, Complicated, News, Telephone, Treatment, Workforce, FDA, Patient, Urinary tract infection, Review, Tebipenem, NASDAQ, Population, Lists of schools in England, NDA, Degenerative disease, P.C, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.

SPERO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc

Retrieved on: 
Tuesday, May 31, 2022
HBR, Telephone, Company, Population, NEW, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, New Drug Application, News, Patient, Complicated, NASDAQ, Review, Therapy, Treatment, FDA, Workforce, Tebipenem, Lists of schools in England, Court, NDA, District court, GLOBE, Pharmaceutical industry, Renewable energy, Practice of law, Spero, Pyelonephritis

NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the Company“) (NASDAQ: SPRO) in the United States District Court for the Eastern District of New York on behalf of a class consisting of those that purchased or otherwise acquired Spero securities between October 28, 2021 and May 2, 2022,

Key Points: 
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
  • If you have incurred losses in Spero Therapeutics, Inc., you may, no later than July 25, 2022, request that the Court appoint you lead plaintiff of the proposed class.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Tuesday, May 31, 2022
HBR, Company, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, News, Patient, Complicated, NASDAQ, Review, Treatment, Complaint, FDA, Workforce, Tebipenem, NDA, District court, GLOBE, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.

Key Points: 
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

EQUITY ALERT: Rosen Law Firm Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Friday, May 27, 2022
Legal, Professional Services, Titan, Spero, Urinary tract infection, Advertising, Food, I-Space (Chinese company), New Drug Application, NASDAQ, WHY, FDA, Workforce, TO, Food and Drug Administration, Lists of schools in England, Facebook, Court, Tebipenem, Pyelonephritis, THE, NDA, LinkedIn, Twitter, Class, Security (finance), Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers – SPRO

Retrieved on: 
Thursday, May 26, 2022
HBR, Company, Urinary tract infection, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Ext, New Drug Application, News, Patient, Complicated, NASDAQ, Review, Infection, Treatment, Degenerative disease, Complaint, FDA, Workforce, LLP, Securities Exchange Act of 1934, Tebipenem, Lists of schools in England, Court, SEC Rule 10b-5, NDA, Person, Pomerantz, District court, Lists of action films, GLOBE, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.

Key Points: 
  • NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

New Real-World Evidence Shows Improvements in Outcomes and Reduction in Healthcare Costs with Guidance® UTI Precision Diagnostic Test Compared to Standard Urine Culture in Patients with Complicated Urinary Tract Infections

Retrieved on: 
Saturday, May 14, 2022
Diabetes, Medical Affairs Bureau, Risk, Urinary tract infection, Sex, Cutis, Infection, Multimedia, Cutis laxa, Patient, View, Health, Solution, Microbiology, Composite, Nature Reviews Microbiology, University Challenge 2013–14, UTI, Medicare Part D, Epidemiology, Medicare, Guidance, AUA, SNF, SUC, PCR, American Urological Association, SVP, Pyelonephritis, Diagnosis, Medical imaging, Pharmaceutical industry, Hospital

IRVINE, Calif., May 14, 2022 /PRNewswire/ -- Real-world evidence from a Medicare database analysis presented today at the 2022 American Urology Association (AUA) Meeting shows that Guidance UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and costs for complicated urinary tract infections (cUTIs) compared to standard urine culture (SUC). The comparative analysis was designed to examine outcomes of one year of cUTI treatment guided by either Guidance UTI or SUC.

Key Points: 
  • The findings reinforce the real-world benefits of Guidance UTI's increased sensitivity, reduced time to results, and P-AST results to patients, providers, and the healthcare system."
  • UTI-related clinical, healthcare use and costs outcomes were then tracked for one year.
  • Guidance UTI testing was associated with 44% lower total costs and 77% lower clinically-advanced costs* compared to SUC, and cUTIs in the Guidance UTI cohort were likelier to be managed successfully as outpatients.
  • The rate of outpatient emergency visits was 13% lower and inpatient admissions were 67% lower when using Guidance UTI compared to SUC.

Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Friday, May 13, 2022
Company, Urinary tract infection, Food, Infection, Webcast, Tuberculosis verrucosa cutis, NASDAQ, Bronchopneumonia, Therapy, Merck, Food and Drug Administration, Conference, Pyelonephritis, Tablet, Fosfomycin, GLOBE, Pharmaceutical industry

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.

Key Points: 
  • DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Spero Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 11, 2022
FDA, Pyelonephritis, Tebipenem, NDA, Infection, Spero, HBR, United, Patient, Urinary tract infection, Adult, Webcast, Degenerative disease, Vaccine, Pharmaceutical industry

Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.

Key Points: 
  • Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.
  • A replay of the presentations will be available on the website following the conclusion of the event.
  • Spero Therapeuticsis a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multidrug resistant bacterial infections and rare diseases.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.